Big Cypress Acquisition Corp.
Status: Deal Closed
U=S+W/2
W=S@11.5
IPO Proceeds, $M | $115.00M |
---|---|
IPO Date | Jan 12, 2021 |
CEO | Samuel J. Reich |
Left Lead | Ladenburg Thalmann |
IPO Cash in Trust | 101.0% |
SPAC Tenor | 15+(3*2) |
IPO Sector |
Healthcare
Life sciences |
IPO Geography | Global |
Target Company | SAB Biotherapeutics |
Deal Announced | Jun 22, 2021 |
Deal Size, $M | $325.38M |
Deal Sector | Healthcare |
Deal Geography | US/Canada |
SEC Filings | www.sec.gov |
Approval Vote | Oct 20, 2021 |
Amendment Vote | TBD |
Closing Date | Oct 22, 2021 |
Formerly BCYP
SABS
SABSW
Price | $4.05 $0.41 |
---|---|
Last closing price | $3.85 |
H/L, today | $3.81 / $4.27 |
H/L, 52-week | $0.37 / $1.45 |
Volume, today | 32,513 |
Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Big Cypress Acquisition Corp.:
- Structure and cap table
- 5 directors & officers
- 23 filings and events
- 2 underwriters
- 3 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
Name | Age | Title |
---|---|---|
Samuel J. Reich | 45 | CEO, CFO and Director |
Jeffrey G. Spragens | 70 | Chairman |
James Martin | 54 | Director |
Ilan Katz | 48 | Director |
Stephen D. Collins, MD, PhD. | 68 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
Ladenburg Thalmann | Joint BR | 9,000,000 | units |
Brookline Capital Markets | Joint BR | 1,000,000 | |
10,000,000 | units | ||
Up-Front UW fee | 1.33 | % | |
Deferred UW fee |
3.67 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.